About
Radiotherapies
Areas of Focus
Categories
RadiopharmaceuticalsBoston & New England
Team (10)
Alex Brown
Alex Brown, MBAChief Operating Officer
Convergent Therapeutics
team_member
Barbara Duncan
Barbara Duncan, MBA
Convergent Therapeutics
team_member
Eric M
Eric M. Sullivan, CPAChief Financial Officer
Convergent Therapeutics
team_member
Jake Simson
Jake Simson, PhD
Convergent Therapeutics
team_member
Jim Trenkle
Jim Trenkle, PhD
Convergent Therapeutics
team_member
Neil Bander
Neil Bander, MD
Convergent Therapeutics
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
1
As Collaborator
1
Total Enrollment
60
By Phase
PHASE2: 1PHASE1: 1
By Status
RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06549465Lead Sponsor
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
PHASE2Recruiting
60 participants
Started: Aug 6, 2024 · Completed: Apr 30, 2027
NCT05567770Collaborator
ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer
PHASE1Withdrawn
Started: Dec 31, 2023 · Completed: Jan 31, 2030
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...